Increased affinity of LDL for their receptors after acipimox treatment in hypertriglyceridemia.

Abstract

The regulation of cellular LDL metabolism by hypertriglyceridemic LDL was tested before and after treatment with acipimox, a nicotinic acid derivative, in 11 type IV hyperlipidemic patients. Large, less dense LDL particles were found in plasma after acipimox treatment. HDL subfractions were only slightly modified, with an increase of dense, cholesteryl ester-enriched and triglyceride-poor HDL3 particles. The LDL (B, E) receptor activity in human skin fibroblasts of LDL isolated before and after treatment was also evaluated. Hypertriglyceridemic LDL proved rather inefficient in regulating receptor activity, with a close to 30% lower capacity than normal LDL to inhibit receptor-mediated uptake and degradation of 125I-LDL. This abnormality was fully corrected after acipimox. The reported findings indicate that acipimox treatment in type IV patients can normalize the defective interaction of hypertriglyceridemic LDL with the LDL (B, E) receptor.

• Authors: G Franceschini, F Bernini, S Michelagnoli, S Bellosta, V Vaccarino, C Torre, F Pazzucconi, R Fumagalli, C R Sirtori
• Journal: European journal of clinical pharmacology (Eur J Clin Pharmacol) Vol. 40 Suppl 1 Pg. S45-8 ( 1991) ISSN: 0031-6970 [Print] Germany
• PMID: 2044643 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Hypolipidemic Agents
• Lipoproteins, LDL
• Pyrazines
• Receptors, LDL
• acipimox

Topics

• Adult
• Humans
• Hypertriglyceridemia (drug therapy)
• Hypolipidemic Agents (therapeutic use)
• Lipoproteins, LDL (metabolism)
• Male
• Middle Aged
• Pyrazines (therapeutic use)
• Receptors, LDL (drug effects, metabolism)